Patent intelligence · US
US 12263202
Method of treating melanocortin-4 receptor pathway-associated disorders
Method of treating melanocortin-4 receptor pathway-associated disorders
Patent details — US 12263202
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 1, 2025
- Expiration
- Mar 27, 2045
- Applicant
- RHYTHM PHARMACEUTICALS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61K38/12, A61K9/0019
Quick answer
US 12263202 (Method of treating melanocortin-4 receptor pathway-associated disorders) is held by RHYTHM PHARMACEUTICALS, INC.. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RHYTHM PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61K38/12, A61K9/0019, A61P, A61P3/04
More from RHYTHM PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12285460
Pharmaceutical compositions
granted -
US 12077612
Peptide compositions
granted -
US 11702448
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted -
US 11129869
Pharmaceutical compositions
granted -
US 10960046
Method of treating melanocortin-4 receptor pathway-associated disorders
granted -
US 10954268
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted -
US 10858399
Peptide compositions
granted
Related coverage
Frequently asked questions
What is US patent 12263202?
US 12263202 (Method of treating melanocortin-4 receptor pathway-associated disorders) is held by RHYTHM PHARMACEUTICALS, INC.. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12263202?
RHYTHM PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12263202 expire?
Our index shows an expiration date of Mar 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.